Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

CollPlant Biotechnologies

DB:CPTA
Snowflake Description

High growth potential with mediocre balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CPTA
DB
$63M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

CollPlant Biotechnologies Ltd., a regenerative medicine company, focuses on developing and commercializing tissue repair products for three-dimensional (3D) bio-printing of tissues and organs, dermal fillers for aesthetics, orthobiologics, and advanced wound care markets in the United States, Canada, and Europe. The last earnings update was 8 days ago. More info.


Add to Portfolio Compare Print
  • CollPlant Biotechnologies has significant price volatility in the past 3 months.
CPTA Share Price and Events
7 Day Returns
5.9%
DB:CPTA
5.2%
DE Biotechs
4.3%
DE Market
1 Year Returns
-
DB:CPTA
-7.4%
DE Biotechs
-14.2%
DE Market
CPTA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
CollPlant Biotechnologies (CPTA) 5.9% -8.5% 11% - - -
DE Biotechs 5.2% -3.3% -20.3% -7.4% 19.5% -9.4%
DE Market 4.3% -9% -21.6% -14.2% -19.6% -25.6%
1 Year Return vs Industry and Market
  • No trading data on CPTA.
  • No trading data on CPTA.
Price Volatility
CPTA
Industry
5yr Volatility vs Market

Value

 Is CollPlant Biotechnologies undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for CollPlant Biotechnologies. This is due to cash flow or dividend data being unavailable. The share price is €8.1.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for CollPlant Biotechnologies's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are CollPlant Biotechnologies's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:CPTA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-2.24
NasdaqCM:CLGN Share Price ** NasdaqCM (2020-04-08) in USD $9.74
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 43.07x
Germany Market PE Ratio Median Figure of 402 Publicly-Listed Companies 17.07x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of CollPlant Biotechnologies.

DB:CPTA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:CLGN Share Price ÷ EPS (both in USD)

= 9.74 ÷ -2.24

-4.35x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • CollPlant Biotechnologies is loss making, we can't compare its value to the Europe Biotechs industry average.
  • CollPlant Biotechnologies is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does CollPlant Biotechnologies's expected growth come at a high price?
Raw Data
DB:CPTA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.35x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
24.4%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.71x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.24x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for CollPlant Biotechnologies, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on CollPlant Biotechnologies's assets?
Raw Data
DB:CPTA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $0.72
NasdaqCM:CLGN Share Price * NasdaqCM (2020-04-08) in USD $9.74
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.37x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.47x
DB:CPTA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:CLGN Share Price ÷ Book Value per Share (both in USD)

= 9.74 ÷ 0.72

13.51x

* Primary Listing of CollPlant Biotechnologies.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • CollPlant Biotechnologies is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess CollPlant Biotechnologies's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. CollPlant Biotechnologies has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is CollPlant Biotechnologies expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
24.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is CollPlant Biotechnologies expected to grow at an attractive rate?
  • CollPlant Biotechnologies's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • CollPlant Biotechnologies's earnings growth is expected to exceed the Germany market average.
  • CollPlant Biotechnologies's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:CPTA Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:CPTA Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 24.4%
DB:CPTA Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 26.7%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 38.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:CPTA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:CPTA Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 38 9 1
2023-12-31 31 7 1
2022-12-31 12 -9 1
2021-12-31 10 -5 1
2020-12-31 28 14 1
2020-04-09
DB:CPTA Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 2 -6 -11
2019-09-30 6 -1 -6
2019-06-30 6 -1 -4
2019-03-31 5 -1 -4
2018-12-31 5 -1 -6
2018-09-30 1 -6 -6
2018-06-30 1 -6 -6
2018-03-31 1 -5 -7
2017-12-31 0 -5 -6
2017-09-30 0 -5 -6
2017-06-30 0 -5 -7
2017-03-31 0 -5 -7

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • CollPlant Biotechnologies's earnings are expected to grow significantly at over 20% yearly.
  • CollPlant Biotechnologies's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:CPTA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from CollPlant Biotechnologies Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:CPTA Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 0.89 0.89 0.89 1.00
2023-12-31 0.68 0.68 0.68 1.00
2022-12-31 -0.98 -0.98 -0.98 1.00
2021-12-31 -0.61 -0.61 -0.61 1.00
2020-12-31 1.55 1.55 1.55 1.00
2020-04-09
DB:CPTA Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -2.24
2019-09-30 -1.24
2019-06-30 -0.82
2019-03-31 -0.80
2018-12-31 -1.43
2018-09-30 -1.64
2018-06-30 -1.82
2018-03-31 -2.24
2017-12-31 -2.27
2017-09-30 -2.52
2017-06-30 -3.09
2017-03-31 -3.27

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if CollPlant Biotechnologies will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess CollPlant Biotechnologies's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
CollPlant Biotechnologies has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has CollPlant Biotechnologies performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare CollPlant Biotechnologies's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • CollPlant Biotechnologies does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare CollPlant Biotechnologies's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare CollPlant Biotechnologies's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
CollPlant Biotechnologies's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from CollPlant Biotechnologies Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:CPTA Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 2.32 -11.16 4.28 3.80
2019-09-30 6.43 -5.80 3.45 5.44
2019-06-30 5.84 -3.80 3.55 5.08
2019-03-31 5.34 -3.77 3.31 4.94
2018-12-31 5.01 -6.25 4.05 3.55
2018-09-30 0.88 -6.49 3.68 3.63
2018-06-30 0.74 -6.33 3.33 3.50
2018-03-31 0.63 -6.56 2.98 4.15
2017-12-31 0.46 -6.05 2.76 3.61
2017-09-30 0.26 -6.23 2.61 3.73
2017-06-30 0.21 -7.14 2.80 4.44
2017-03-31 0.15 -7.01 2.85 4.25
2016-12-31 0.08 -7.25 2.87 4.36
2016-09-30 0.02 -7.37 2.33 4.98
2016-06-30 -6.57 2.23 4.35
2016-03-31 -6.06 2.09 3.93
2015-12-31 -4.79 1.78 3.04
2015-09-30 -3.92 1.42 2.64
2015-06-30 -3.59 1.24 2.51
2015-03-31 -3.19 0.99 2.38
2014-12-31 -3.34 1.00 2.50
2014-09-30 -3.85 1.08 2.82
2014-06-30 -4.33 1.20 3.08
2014-03-31 -4.38 1.14 3.20
2013-12-31 -4.75 1.08 3.59
2013-09-30 -4.68 1.00 3.62
2013-06-30 -4.90 1.03 3.82

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if CollPlant Biotechnologies has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if CollPlant Biotechnologies has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if CollPlant Biotechnologies improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess CollPlant Biotechnologies's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
CollPlant Biotechnologies has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is CollPlant Biotechnologies's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up CollPlant Biotechnologies's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • CollPlant Biotechnologies is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • CollPlant Biotechnologies's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of CollPlant Biotechnologies's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 210x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from CollPlant Biotechnologies Company Filings, last reported 3 months ago.

DB:CPTA Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 4.09 0.02 3.79
2019-09-30 -1.37 5.47 5.74
2019-06-30 1.83 0.04 1.74
2019-03-31 3.10 0.04 3.71
2018-12-31 5.42 0.04 5.35
2018-09-30 3.70 0.05 2.60
2018-06-30 3.54 0.06 2.56
2018-03-31 5.01 0.00 3.96
2017-12-31 2.62 3.64 5.13
2017-09-30 0.60 0.00 2.32
2017-06-30 1.60 0.00 1.30
2017-03-31 2.02 0.00 1.22
2016-12-31 1.34 0.00 0.99
2016-09-30 3.07 0.00 2.12
2016-06-30 4.25 0.00 2.88
2016-03-31 2.90 0.00 1.52
2015-12-31 2.51 0.00 1.36
2015-09-30 3.86 0.00 2.22
2015-06-30 2.17 0.00 0.36
2015-03-31 2.75 0.00 1.77
2014-12-31 3.67 0.00 2.84
2014-09-30 4.82 0.00 3.87
2014-06-30 5.94 0.00 4.84
2014-03-31 6.69 0.00 5.54
2013-12-31 7.81 0.00 6.86
2013-09-30 1.22 0.00 0.37
2013-06-30 2.08 0.00 0.67
  • CollPlant Biotechnologies's level of debt (0.6%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if CollPlant Biotechnologies's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • CollPlant Biotechnologies has less than a year of cash runway based on current free cash flow.
  • CollPlant Biotechnologies has less than a year of cash runway if free cash flow continues to grow at historical rates of 0.8% each year.
X
Financial health checks
We assess CollPlant Biotechnologies's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. CollPlant Biotechnologies has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is CollPlant Biotechnologies's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from CollPlant Biotechnologies dividends.
If you bought €2,000 of CollPlant Biotechnologies shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate CollPlant Biotechnologies's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate CollPlant Biotechnologies's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:CPTA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.6%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:CPTA Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-04-09

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as CollPlant Biotechnologies has not reported any payouts.
  • Unable to verify if CollPlant Biotechnologies's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of CollPlant Biotechnologies's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as CollPlant Biotechnologies has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess CollPlant Biotechnologies's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can CollPlant Biotechnologies afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. CollPlant Biotechnologies has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of CollPlant Biotechnologies's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Yehiel Tal
COMPENSATION $1,533,000
AGE 67
TENURE AS CEO 10.3 years
CEO Bio

Mr. Yehiel Tal has been the Chief Executive Officer of Collplant Holdings Ltd. since January 2010. Mr. Tal Co-founded Regentis Biomaterials, Ltd. in 2004 and served as its Chief Executive Officer. He has 17 years of management experience in Israeli and American high-tech and biotech industries. Prior to Regentis Biomaterials, he served as Vice-President of Business Development at ProChon BioTech Ltd. He also served as Vice President of Marketing and Business Development at OrthoScan Technologies Ltd., Vice President of Marketing and Sales at Nextec Ltd. and Director of Business Development and Business Unit Manager at Kulicke and Soffa Industries, Inc. He served as Director of Regentis Biomaterials, Ltd. Mr. Tal holds a Bachelor's and a Master's degree in Mechanical Engineering from the Technion, Israel Institute of Technology.

CEO Compensation
  • Yehiel's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Yehiel's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the CollPlant Biotechnologies management team in years:

9.3
Average Tenure
61
Average Age
  • The average tenure for the CollPlant Biotechnologies management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Oded Shoseyov

TITLE
Founder & Chief Scientist
COMPENSATION
$946K
AGE
63
TENURE
16.3 yrs

Eran Rotem

TITLE
Deputy CEO & CFO
COMPENSATION
$2M
AGE
51
TENURE
8.3 yrs

Yehiel Tal

TITLE
Chief Executive Officer
COMPENSATION
$2M
AGE
67
TENURE
10.3 yrs

Ilana Belzer

TITLE
Chief Operations Officer
AGE
59
TENURE
4.5 yrs
Board of Directors

Roger Pomerantz

TITLE
Independent Chairman of the Board
AGE
62
TENURE
0.2 yrs

Avram Hershko

TITLE
Member of the Scientific Advisory Board
AGE
82

Vicki Rosen

TITLE
Member of the Scientific Advisory Board

Abhay Pandit

TITLE
Member of the Scientific Advisory Board

Joseph Lane

TITLE
Member of the Scientific Advisory Board & Member of the Clinical Advisory Board

Ofer Levy

TITLE
Member of the Scientific Advisory Board & Member of the Clinical Advisory Board

Avri Havron

TITLE
Independent Director
AGE
71
TENURE
3.9 yrs

Scott Rodeo

TITLE
Member of the Clinical Advisory Board

Thomas Serena

TITLE
Member of the Clinical Advisory Board

Gabi Agar

TITLE
Member of the Clinical Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
12. Aug 19 Buy Ami Sagyp Individual 06. Aug 19 06. Aug 19 140,000 €3.13 €437,668
20. Jun 19 Buy Ami Sagyp Individual 30. May 19 19. Jun 19 49,483 €5.10 €249,489
X
Management checks
We assess CollPlant Biotechnologies's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. CollPlant Biotechnologies has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

CollPlant Biotechnologies Ltd., a regenerative medicine company, focuses on developing and commercializing tissue repair products for three-dimensional (3D) bio-printing of tissues and organs, dermal fillers for aesthetics, orthobiologics, and advanced wound care markets in the United States, Canada, and Europe. The company’s products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. Its products include VergenixSTR, a soft tissue repair matrix intended for treatment of tendinopathy; VergenixFG, a wound-filling flowable gel for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; and BioInks for 3D printing of tissues and organs. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.

Details
Name: CollPlant Biotechnologies Ltd.
CPTA
Exchange: DB
Founded: 2004
$57,894,695
6,463,695
Website: http://www.collplant.com
Address: CollPlant Biotechnologies Ltd.
Weizmann Science Park,
4 Oppenheimer,
Rehovot,
7670104,
Israel
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM CLGN SPONSORED ADR NE Nasdaq Capital Market US USD 23. Mar 2015
DB CPTA SPONSORED ADR NE Deutsche Boerse AG DE EUR 23. Mar 2015
Number of employees
Current staff
Staff numbers
38
CollPlant Biotechnologies employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/09 00:23
End of day share price update: 2020/04/08 00:00
Last estimates confirmation: 2020/04/03
Last earnings filing: 2020/04/01
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.